A new study that came up on Wednesday states that Swiss drug maker Novartis AG’s cancer-fighting drug Gleevec can help treating chronic myeloid leukemia ever after five years of use.
During the course of study, it was found that 89 percent of the volunteers who started taking drug Gleevec also known as imatinib for treating chronic myeloid leukemia (CML), remained alive when compared with patients who didn’t take this medicine. However, it was also found that some patients developed resistance to this drug over the five-year span.
This is really a good finding because earlier the survival rate of people with this disease hardly less than 50 percent but with the advent of this drug, experts are hoping that survival rate may easily touch 95 percent.
Image credit: Firstmed